Ovarian tumor

Results: 281



#Item
11 I bodywise much as $14 million among approximately 70 researchers.

I bodywise much as $14 million among approximately 70 researchers. "Some of the most recent research is the most exciting," says Lauder,

Add to Reading List

Source URL: amyblumenfeld.com

Language: English - Date: 2015-04-09 14:57:54
12DOI:.CANPhosphorylation of ATR-Interacting Protein on Ser239 Mediates an Interaction with Breast-Ovarian Cancer Susceptibility 1 and Checkpoint Function Monica Venere, Andrew Snyder, Omar Zghei

DOI:.CANPhosphorylation of ATR-Interacting Protein on Ser239 Mediates an Interaction with Breast-Ovarian Cancer Susceptibility 1 and Checkpoint Function Monica Venere, Andrew Snyder, Omar Zghei

Add to Reading List

Source URL: molbio.unige.ch

Language: English - Date: 2011-06-08 05:03:14
13Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification

Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification

Add to Reading List

Source URL: www.ovarianresearch.com

Language: English
    14Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms

    Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms

    Add to Reading List

    Source URL: www.biomedcentral.com

    Language: English
    15Award ID: DP150091 Project Title: Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy Award Mechanism: Bridging the Gap: Early Translational Research Awards

    Award ID: DP150091 Project Title: Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy Award Mechanism: Bridging the Gap: Early Translational Research Awards

    Add to Reading List

    Source URL: www.cprit.state.tx.us

    Language: English - Date: 2014-11-20 01:49:27
    16Proteomics Clin. Appl. 2013, 7, 1–7 1 DOIprca

    Proteomics Clin. Appl. 2013, 7, 1–7 1 DOIprca

    Add to Reading List

    Source URL: clic-imaging.com

    Language: English - Date: 2014-03-26 11:42:10
    17PRESS RELEASE October 2nd, 2014 HEALTH | BIOTECHNOLOGIES | INNOVATION | FLUORESCENCE IMAGING | SURGERY | CANCER Fluoptics speeds up the developpement

    PRESS RELEASE October 2nd, 2014 HEALTH | BIOTECHNOLOGIES | INNOVATION | FLUORESCENCE IMAGING | SURGERY | CANCER Fluoptics speeds up the developpement

    Add to Reading List

    Source URL: www.fluoptics.com

    Language: English - Date: 2014-10-03 08:53:39
    18Microsoft Word - BRCA Share PREurope Version

    Microsoft Word - BRCA Share PREurope Version

    Add to Reading List

    Source URL: www.inserm-transfert.fr

    Language: English - Date: 2015-04-22 06:57:43
    19Repeated intratumoral administration of ONCOS-102 leads to robust cellular and transcriptional immune activation at tumor site in an ovarian cancer patient Vassilev L.1, Hemminki A.2, Joensuu T.3, Jäger E.4, Karbach J.4

    Repeated intratumoral administration of ONCOS-102 leads to robust cellular and transcriptional immune activation at tumor site in an ovarian cancer patient Vassilev L.1, Hemminki A.2, Joensuu T.3, Jäger E.4, Karbach J.4

    Add to Reading List

    Source URL: oncos.com

    Language: English - Date: 2014-07-10 04:16:00
    20The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe

    The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe

    Add to Reading List

    Source URL: www.ceruleanrx.com

    Language: English - Date: 2015-06-01 11:12:23